Facebook picto   picto linkdink   picto tiwter


Feb 14, 2023
EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2022 Revenue


EDAP TMS SA, a global leader in robotic energy-based therapies, today announced preliminary unaudited fourth quarter and full year 2022 revenue and other financial highlights.

“We finished 2022 with strong fourth quarter and full year revenue, driven by successful execution of our U.S. Focal One HIFU business,” said Marc Oczachowski, Chairman and Chief Executive Officer of EDAP TMS. “We sold 15 Focal One machines in 2022, as compared to seven in 2021. This notable increase further validates the growing momentum and interest amongst leading clinicians and hospital providers in offering Focal One as a necessary treatment option to select prostate cancer patients.”

Ryan Rhodes, Chief Executive Officer of EDAP Technomed Inc., stated, “We recorded nine Focal One transactions in the U.S. during the fourth quarter, including six machine sales and threeoperating leases. As our pipeline continues to strengthen, we see a good mix of both large academic medical centers as well as community hospitals who understand the necessity and value of providing access to Focal One Robotic HIFU technology to an appropriate subset of prostate cancer patients. In addition, the Medicare reimbursement increase that went into effect on January 1stappropriately allows more providers to consider the investment in obtaining HIFU technology. We believe these actions together will continue to support our growing US commercial momentum in 2023.”